Hikma celebrates 20 years on the London Stock Exchange

London – 20 November 2025

We’re proud to mark 20 years as a publicly listed company on the London Stock Exchange. Since our initial public offering in November 2005, we’ve expanded our global footprint across North America, Europe, and the MENA region. Today, we operate 29 manufacturing facilities, R&D hubs in three key locations, offer a portfolio of over 800 products, and employ more than 9,500 people across our Injectables, Rx, and Branded businesses. 

To celebrate this milestone, our leadership team joined colleagues and stakeholders at a market close ceremony at the London Stock Exchange. The event honoured the contributions of those who have supported our growth over the past two decades.

Our continued performance reflects the strength of our diversified business model, with all three businesses contributing to topline growth. Looking ahead, we will sustain that momentum through operational excellence and an unwavering commitment to quality. 

Ongoing investment in R&D and targeted business development ensures we continue to deliver high-quality, affordable medicines to patients across our markets, while strategic investment in technical capabilities and manufacturing capacity positions us for long term success and sustained growth.

We’re grateful to our colleagues, customers, healthcare partners, and shareholders for their continued support, and we look forward to building on this strong foundation as we keep putting better health within reach, every day.